Ramy Farid

October 14, 2026

Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates. Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.

October 15, 2026

Schrödinger (SDGR) Announces New Battery Research, Analyst Targets Rise. Schrödinger’s research team published a study in Nature that provides new insights into lithium‑ion battery chemistry, showcasing the company’s computational chemistry capabilities. Analyst houses TD Cowen and BMO Capital each lifted their price targets, citing the potential impact of the battery work and broader AI applications. At the same time, other analysts expressed mixed views on the company’s AI growth, resulting in a modest upward adjustment to its fair‑value estimate.

October 11, 2026

LLY Stock Dip News Unrelated to GPCR. Recent headlines focus on Eli Lilly (LLY) stock performance, which does not provide specific news about Structure Therapeutics (GPCR). While GPCR technical indicators show extreme oversold conditions, the provided news articles do not contain company-specific updates or developments for this symbol.